Enhancement of Adenovirus Delivery after Ultrasound-Stimulated Therapy in a Cancer Model

Anna G. Sorace, Jason M. Warram, Marshall Mahoney, Kurt R. Zinn, Kenneth Hoyt

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Improving the efficiency of adenovirus (Ad) delivery to target tissues has the potential to advance the translation of cancer gene therapy. Ultrasound (US)-stimulated therapy uses microbubbles (MBs) exposed to low-intensity US energy to improve localized delivery. We hypothesize that US-stimulated gene therapy can improve Ad infection in a primary prostate tumor through enhanced tumor uptake and retention of the Ad vector. Invitro studies were performed to analyze the degree of Ad infectivity after application of US-stimulated gene therapy. A luciferase-based Ad on a ubiquitous cytomegalovirus (CMV) promoter (Ad5/3-CMV-Luc) was used in an animal model of prostate cancer (bilateral tumor growth) to evaluate Ad transduction efficiency after US-stimulated therapy. Bioluminescence imaging was employed for invivo analysis to quantify Ad infection within the tumor. Invitro studies revealed no difference in Ad transduction between groups receiving US-stimulated therapy using high, low or sham US intensity exposures at various multiplicities of infection (MOIs) (p=0.80). Invivo results indicated that tumors receiving US-stimulated therapy after intra-tumoral injection of Ad5/3-CMV-Luc (1×106 plaque-forming units) exhibited a 95.1% enhancement in tumor delivery compared with control tumors receiving sham US (p=0.03). US-stimulated therapy has significant potential to immediately affect Ad-based cancer gene therapy by improving virus bioavailability in target tissues.

Original languageEnglish (US)
Pages (from-to)2374-2381
Number of pages8
JournalUltrasound in Medicine and Biology
Volume39
Issue number12
DOIs
StatePublished - Jan 1 2013

Fingerprint

adenoviruses
Adenoviridae
therapy
delivery
cancer
tumors
gene therapy
augmentation
Genetic Therapy
Cytomegalovirus
Neoplasms
Adenoviridae Infections
infectious diseases
Neoplasm Genes
oncogenes
Therapeutics
Microbubbles
bioluminescence
Luciferases
bioavailability

Keywords

  • Adenovirus
  • Cancer
  • Gene therapy
  • Microbubble contrast agent
  • Transduction
  • Ultrasound

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Biophysics
  • Radiology Nuclear Medicine and imaging

Cite this

Enhancement of Adenovirus Delivery after Ultrasound-Stimulated Therapy in a Cancer Model. / Sorace, Anna G.; Warram, Jason M.; Mahoney, Marshall; Zinn, Kurt R.; Hoyt, Kenneth.

In: Ultrasound in Medicine and Biology, Vol. 39, No. 12, 01.01.2013, p. 2374-2381.

Research output: Contribution to journalArticle

Sorace, Anna G. ; Warram, Jason M. ; Mahoney, Marshall ; Zinn, Kurt R. ; Hoyt, Kenneth. / Enhancement of Adenovirus Delivery after Ultrasound-Stimulated Therapy in a Cancer Model. In: Ultrasound in Medicine and Biology. 2013 ; Vol. 39, No. 12. pp. 2374-2381.
@article{1f8978b3152d4e04b1250af671eeae66,
title = "Enhancement of Adenovirus Delivery after Ultrasound-Stimulated Therapy in a Cancer Model",
abstract = "Improving the efficiency of adenovirus (Ad) delivery to target tissues has the potential to advance the translation of cancer gene therapy. Ultrasound (US)-stimulated therapy uses microbubbles (MBs) exposed to low-intensity US energy to improve localized delivery. We hypothesize that US-stimulated gene therapy can improve Ad infection in a primary prostate tumor through enhanced tumor uptake and retention of the Ad vector. Invitro studies were performed to analyze the degree of Ad infectivity after application of US-stimulated gene therapy. A luciferase-based Ad on a ubiquitous cytomegalovirus (CMV) promoter (Ad5/3-CMV-Luc) was used in an animal model of prostate cancer (bilateral tumor growth) to evaluate Ad transduction efficiency after US-stimulated therapy. Bioluminescence imaging was employed for invivo analysis to quantify Ad infection within the tumor. Invitro studies revealed no difference in Ad transduction between groups receiving US-stimulated therapy using high, low or sham US intensity exposures at various multiplicities of infection (MOIs) (p=0.80). Invivo results indicated that tumors receiving US-stimulated therapy after intra-tumoral injection of Ad5/3-CMV-Luc (1×106 plaque-forming units) exhibited a 95.1{\%} enhancement in tumor delivery compared with control tumors receiving sham US (p=0.03). US-stimulated therapy has significant potential to immediately affect Ad-based cancer gene therapy by improving virus bioavailability in target tissues.",
keywords = "Adenovirus, Cancer, Gene therapy, Microbubble contrast agent, Transduction, Ultrasound",
author = "Sorace, {Anna G.} and Warram, {Jason M.} and Marshall Mahoney and Zinn, {Kurt R.} and Kenneth Hoyt",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.ultrasmedbio.2013.07.017",
language = "English (US)",
volume = "39",
pages = "2374--2381",
journal = "Ultrasound in Medicine and Biology",
issn = "0301-5629",
publisher = "Elsevier USA",
number = "12",

}

TY - JOUR

T1 - Enhancement of Adenovirus Delivery after Ultrasound-Stimulated Therapy in a Cancer Model

AU - Sorace, Anna G.

AU - Warram, Jason M.

AU - Mahoney, Marshall

AU - Zinn, Kurt R.

AU - Hoyt, Kenneth

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Improving the efficiency of adenovirus (Ad) delivery to target tissues has the potential to advance the translation of cancer gene therapy. Ultrasound (US)-stimulated therapy uses microbubbles (MBs) exposed to low-intensity US energy to improve localized delivery. We hypothesize that US-stimulated gene therapy can improve Ad infection in a primary prostate tumor through enhanced tumor uptake and retention of the Ad vector. Invitro studies were performed to analyze the degree of Ad infectivity after application of US-stimulated gene therapy. A luciferase-based Ad on a ubiquitous cytomegalovirus (CMV) promoter (Ad5/3-CMV-Luc) was used in an animal model of prostate cancer (bilateral tumor growth) to evaluate Ad transduction efficiency after US-stimulated therapy. Bioluminescence imaging was employed for invivo analysis to quantify Ad infection within the tumor. Invitro studies revealed no difference in Ad transduction between groups receiving US-stimulated therapy using high, low or sham US intensity exposures at various multiplicities of infection (MOIs) (p=0.80). Invivo results indicated that tumors receiving US-stimulated therapy after intra-tumoral injection of Ad5/3-CMV-Luc (1×106 plaque-forming units) exhibited a 95.1% enhancement in tumor delivery compared with control tumors receiving sham US (p=0.03). US-stimulated therapy has significant potential to immediately affect Ad-based cancer gene therapy by improving virus bioavailability in target tissues.

AB - Improving the efficiency of adenovirus (Ad) delivery to target tissues has the potential to advance the translation of cancer gene therapy. Ultrasound (US)-stimulated therapy uses microbubbles (MBs) exposed to low-intensity US energy to improve localized delivery. We hypothesize that US-stimulated gene therapy can improve Ad infection in a primary prostate tumor through enhanced tumor uptake and retention of the Ad vector. Invitro studies were performed to analyze the degree of Ad infectivity after application of US-stimulated gene therapy. A luciferase-based Ad on a ubiquitous cytomegalovirus (CMV) promoter (Ad5/3-CMV-Luc) was used in an animal model of prostate cancer (bilateral tumor growth) to evaluate Ad transduction efficiency after US-stimulated therapy. Bioluminescence imaging was employed for invivo analysis to quantify Ad infection within the tumor. Invitro studies revealed no difference in Ad transduction between groups receiving US-stimulated therapy using high, low or sham US intensity exposures at various multiplicities of infection (MOIs) (p=0.80). Invivo results indicated that tumors receiving US-stimulated therapy after intra-tumoral injection of Ad5/3-CMV-Luc (1×106 plaque-forming units) exhibited a 95.1% enhancement in tumor delivery compared with control tumors receiving sham US (p=0.03). US-stimulated therapy has significant potential to immediately affect Ad-based cancer gene therapy by improving virus bioavailability in target tissues.

KW - Adenovirus

KW - Cancer

KW - Gene therapy

KW - Microbubble contrast agent

KW - Transduction

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=84887816434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887816434&partnerID=8YFLogxK

U2 - 10.1016/j.ultrasmedbio.2013.07.017

DO - 10.1016/j.ultrasmedbio.2013.07.017

M3 - Article

C2 - 24063960

AN - SCOPUS:84887816434

VL - 39

SP - 2374

EP - 2381

JO - Ultrasound in Medicine and Biology

JF - Ultrasound in Medicine and Biology

SN - 0301-5629

IS - 12

ER -